NYMXF (Nymox Pharmaceutical) FCF Margin %: 0.00% (As of Dec. 2024)


What is Nymox Pharmaceutical FCF Margin %?

Nymox Pharmaceutical NYMXF +9.09% FCF Margin % is 0.00% as of Dec. 2024.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Nymox Pharmaceutical's Free Cash Flow for the three months ended in Dec. 2024 was $-0.72 Mil. Nymox Pharmaceutical's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Nymox Pharmaceutical's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Nymox Pharmaceutical's current FCF Yield % is -6.32%.

The historical rank and industry rank for Nymox Pharmaceutical's FCF Margin % or its related term are showing as below:


NYMXF's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -84.65
* Ranked among companies with meaningful FCF Margin % only.

Nymox Pharmaceutical FCF Margin % Related Terms

Nymox Pharmaceutical FCF Margin % Historical Data

* Premium members only.

The historical data trend for Nymox Pharmaceutical's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nymox Pharmaceutical FCF Margin % Chart

Nymox Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -201,000.00 0.00 0.00 0.00 0.00

Nymox Pharmaceutical Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Sep24 Dec24
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 17,940.00 0.00 0.00

NYMXF vs LYRA, RNAZ, TOVX: FCF Margin % Comparison

For the Biotechnology subindustry, Nymox Pharmaceutical's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nymox Pharmaceutical FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's FCF Margin % falls into.


Nymox Pharmaceutical FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Nymox Pharmaceutical's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-2.601/0
= %

Nymox Pharmaceutical's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-0.717/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Nymox Pharmaceutical (NYMXF) has a FCF Margin % of 0.00% as of Dec. 2024. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Nymox Pharmaceutical and its competitors.
Is Nymox Pharmaceutical's FCF Margin % too high?
Nymox Pharmaceutical's current FCF Margin % is 0.00%.
How does Nymox Pharmaceutical's FCF Margin % compare to LYRA and RNAZ?
Nymox Pharmaceutical's FCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Nymox Pharmaceutical and its competitors. Nymox Pharmaceutical's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nymox Pharmaceutical stock overvalued right now?
Nymox Pharmaceutical (NYMXF) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Nymox Pharmaceutical (NYMXF), the current FCF Margin % is 0.00% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nymox Pharmaceutical Business Description

Address Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and low-grade localized prostate cancer. The company also has an extensive patent portfolio covering its investigational drug as well as other therapeutic and diagnostic indications. It also has U.S. and patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The company operates in one reportable segment, focused on researching and developing products for the aging population.